iwCLL 2023 – Lydia Scarfò
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationLydia Scarfò describes prophylactic and therapeutic measures against SARS-CoV-2 in patients with CLL, potential risk factors for mortality, seroconversion in response to vaccination and areas of research and unmet need regarding prevention and treatment of COVID-19 infections in patients with CLL and hematologic malignancies in general. Finally, she gives insights into the clinical implications of XPO1 mutations in CLL patients.